Strategic Acquisition Post-acquisition by Jabil in 2025, Pii gains access to expanded engineering, manufacturing, and supply chain capabilities, creating cross-sell opportunities into Jabil’s global customer base and scale advantages for larger programs.

Aseptic and Fill Capacity Pii specializes in aseptic filling, lyophilization, and high potency handling with scalable solutions, suggesting opportunities to partner with pharmaceutical firms seeking CDMO support for sterile injectables, biologics-adjacent dosage forms, and high-potency products.

IND Readiness Platform The Accelevate Early Development Platform accelerates IND readiness to 100 days, which can be marketed to small-to-mid-sized biotech and specialty pharma clients needing rapid development-to-production handoff.

Expansion Investments Investments in prefilled syringe capabilities, automated fill/finish, labeling, and visual inspection indicate readiness to pursue clients with complex packaging, serialization, and advanced fill/finish projects in high-value markets.

Global and Tech Ecosystem A technology stack including AWS, Google Cloud, Azure, and analytics/ad tagging plus a global partner in Jabil suggests cross-sell into digital quality systems, data security, and cloud-enabled manufacturing services for regulated pharma clients seeking modern, integrated operations.